Aurobindo Pharma has received an approval from the US Food and Drug Administration (USFDA) to manufacture and market Modafinil Tablets USP 100mg and 200mg (ANDA 202566). The product is ready for launch. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.
Modafinil Tablets are the generic equivalent of Cephalon, Inc’s Provigil Tablets. Modafinil Tablets USP 100mg and 200mg are indicated in adults for treatment of narcolepsy, shift work sleep disorders and excessive daytime sleepiness associated with obstructive sleep apnea. According to IMS for the twelve months ending March 2012, the product has a market size of approximately $1.2 billion.
Aurobindo now has a total of 160 ANDA approvals (135 Final approvals including 1 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: